Scientists Develop Blood Test That Detects 50 Types of Cancer

A team of international researchers has developed a groundbreaking blood test capable of detecting over 50 different types of cancer at early stages. Known as a “multi-cancer early detection test,” the new technology could transform cancer screening and potentially save millions of lives.

The test, developed by scientists at GRAIL (a healthcare company specializing in early cancer detection), uses a technique called liquid biopsy. It analyzes DNA fragments shed by tumors into the bloodstream, known as circulating tumor DNA (ctDNA). By identifying specific patterns and mutations in this genetic material, the test can not only detect cancer but also pinpoint its origin in the body.

In clinical trials involving over 100,000 participants across the United States and Europe, the test showed an accuracy rate of over 90% in detecting some of the deadliest cancers, including pancreatic, ovarian, and esophageal cancer — all of which are often diagnosed too late.

Dr. Helen Marks, one of the lead researchers, stated:

“This is a major advancement in oncology. Detecting cancer early significantly increases the chance of successful treatment, and this test can be a game changer, especially for cancers with no regular screening methods.”

The test is currently undergoing regulatory review and is expected to be available in select hospitals and clinics by the end of 2025. Experts caution that while the test is not a replacement for traditional screenings like mammograms or colonoscopies, it could become a powerful complementary tool in the fight against cancer.

If approved widely, this test could usher in a new era of non-invasive, comprehensive cancer diagnostics.